$NWBO Post clips from around the web.. FLASKWORKS'

New Post Public Reply Private Reply Replies (0) Message Board
mc67
1,684
$NWBO Post clips from around the web..

FLASKWORKS' owned by NWBO, its individualized treatment production device, MIcroDen, has already been manufactured by CORNING and is currently being marketed to pharmas producing similar treatments requiring sterilized environments for culture/medication production. FLASKWORKS and Corning would not have had MicroDen bought from them by NWBO with stock options without having done their own analysis of the NWBO's profitability.

NWBO is ready to hit the ground running.

If the results were bad news, we would have heard by now. My bet is the final data is a go and NWBO is in the process of writing the article detailing scientifically its success and arranging for publication of positive results in a major medical journal. That takes time to fit into publication schedules. A treatment break thru of this magnitude is not simply publicized in a pedestrian press release. Maybe no. Maybe yes. I say yes!

Good news is coming!



Here is an extract from
Herald-Tribune today's article:
"However, and this is a huge however, if the trial had failed, SEC rules require that they had to reveal that to investors within four days.

Instead, weeks have passed without a word, so by inference we now know the trial was a success. This is the largest and longest such trial ever run and the only one of more than 400 to reach a happy result.

The lead investigators and their collaborators are hard at work on a paper to be published in a major medical journal. Until then, the company is in a “quiet period.”"



I wish that we could really infer that the trial is a success. Fact is, the FDA makes that decision. They can't decide until they have an application and all of the supporting data. The odds of approval are higher now for sure, but currently there is no telling whether the FDA will move to make a label so NWBO can market/help people; or demand a PIV; or what... all I'm sayin' is that there will be a time to make yourself fat or get yourself slaughtered.




Its getting clearer with each passing day that the TLD will be favorable! Action today may be leakage of data about to be released!!




At this time very little downside risk. If this failed we would have known by now based on SEC 4 day rule. Remember, the FDA mandated cross over option in this trial so there is absolutely no way the would fail this study based on that fact. Agree, it may be more difficult to analyze but I am certain the statistics will be correctly identified. My money is on approval by the UK, Germany and Canada. LP knew that the FDA is a puppet for lobbyists so she was brilliant in her decision to develop the trial in 4 countries! Merry Christmas longs

Northwest Biotherapeutics Inc. (NWBO) Stock Research Links

NWBO Board Company Profile Buy Rating Time & Sales News Filings Financials
$MJ
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cloud Software Group Amends $2B Cash Tender Offer

Updated Category News Views 71

Cloud Software Group is stirring the pot with an amendment that'll have bondholders looking twice at their portfolios. On November 3, 2026, the company announced a tweak to its cash tender offer, bumping up the payment for its 9.00% Senior Secured Second Lien Notes due 2029. The payout now jumps from $1,017.50 to $1,022.50 for each $1,000 of principal. If you're holding...

Continue Reading
ACLM and eClinicalWorks Expand Lifestyle Medicine Reach

Updated Category News Views 92

Changing the Game with Lifestyle Medicine When it comes to healthcare, you're always going to have the skeptics grousing about the old ways. But what happens when you take an old idea and turbocharge it with modern tech? That's where the American College of Lifestyle Medicine (ACLM) and eClinicalWorks step in. They’re throwing a new wrench into the electronic health...

Continue Reading
STVN's GLP-1 Fumble Sparks Shareholder Scrutiny

Updated Category News Views 35

The Storm Hits Stevanato: GLP-1 Blues Well, ain't this a fine pickle for Stevanato Group S.p.A. (NYSE:STVN). November 3, 2026, turned into quite the ride for those holding STVN shares. A tough third-quarter report dropped like a ton of bricks, driving the shares down after they coughed up a lower outlook for GLP-1 volumes in 2027. If you've been in the game long enough,...

Continue Reading
Tamagotchi Turns 30: Roblox Event Connects Worlds

Updated Category News Views 17

A New Chapter for an Old Favorite Dust off your digital pets, folks! Tamagotchi is not just a thing of the past. It's busting out of its shell to celebrate a big 3-0 with a splash—and get this—on Roblox. Who would've thought a plastic egg with pixels would still be out there thriving in the ether of childhood nostalgia three decades later? But it is, and it’s taking...

Continue Reading
ROBOTWORLD 2026: AI Reshapes Industrial Horizons

Updated Category News Views 48

A Grand Gathering of Robotics Minds Walking into KINTEX, Seoul's suburban behemoth of an exhibition center, you'll find a buzz that rivals the excitement of a stock floor on earnings day. It's ROBOTWORLD 2026, a stage set for tech titans and ambitious startups alike, all throwing in their chips on AI and robotics. From November 4th to 7th, 402 companies hailing from 17...

Continue Reading
3M's Huge Settlement: Navigating A Looming Legal Fog

Updated Category News Views 94

The latest chapter in 3M’s legal saga reads like a courtroom drama, but this time, the company's shelling out big bucks to sidestep prolonged courtroom battles. They're committing to a $5.8 billion payout over several years, aiming to put a lid on a massive batch of PFAS-related lawsuits. It’s like they’re cleaning the spill with a velvet mop, but the trick is...

Continue Reading
DarioHealth Taps Palumbo to Drive Healthcare Evolution

Updated Category News Views 0

Strategic Leadership for an Evolving Market Prepare your portfolios, folks. DarioHealth Corp. (NASDAQ:DRIO) is gearing up to ride a seismic shift in healthcare. John R. Palumbo's appointment as Chairman of the Board marks a bold move as Dario looks to dominate the new convergence of consumer-directed and payer-funded healthcare. This isn't just a change of guard; it's a...

Continue Reading
VAB's Pharma Ad Guide: Emerging Trends and Insights

Updated Category News Views 191

Pharma's not just popping pills anymore; it's a whole show on multiscreen TV. The Video Advertising Bureau (VAB) just dropped a bombshell of a guide called The Pharmacy, diving into the state of pharmaceutical direct-to-consumer (DTC) advertising. Over the past year and a half, VAB's been grilling agencies, media folks, and anyone else with skin in the game to sketch the...

Continue Reading
SWFI's I20 Summit Spotlights 3,000 Promising Start-Ups

Updated Category News Views 101

Spotlight on Emerging Titans: The Future 100 Watchlist The Sovereign Wealth Fund Institute is rattling the investment cages with their latest stunt, the 'Future 100 Watchlist.' Hot off the press, this list is parading nearly 3,000 start-ups that are biting at the heels of future success. It's high stakes and higher hopes between December 11-16 at Miami's I20 Summit, where...

Continue Reading
Compass Faces Securities Fraud Suit: Deadline Looms

Updated Category News Views 45

Compass's Legal Rumble: Shareholders Take Note You know there’s trouble when a firm’s every effort at glassy-eyed optimism is slapped with a lawsuit. We've seen this song and dance far too often, and now Compass, Inc. (NYSE: COMP) takes center stage. Schall, Brown & Schwartz LLP is rallying the troops for a knock-down-drag-out class action lawsuit, accusing Compass of...

Continue Reading
s of Cautious Optimism - Continue Reading" aria-label="Continue reading: Farmer Sentiment Rises, Hints of Cautious Optimism"> Continue Reading